Q1 Earnings Estimate for AKBA Issued By Leerink Partnrs

Akebia Therapeutics, Inc. (NASDAQ:AKBA) – Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Akebia Therapeutics in a report issued on Monday, April 28th. Leerink Partnrs analyst R. Ruiz anticipates that the biopharmaceutical company will post earnings of ($0.01) per share for the quarter. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Akebia Therapeutics’ current full-year earnings is ($0.30) per share. Leerink Partnrs also issued estimates for Akebia Therapeutics’ Q2 2025 earnings at ($0.02) EPS, Q3 2025 earnings at ($0.03) EPS, Q4 2025 earnings at ($0.01) EPS, FY2025 earnings at ($0.07) EPS, FY2026 earnings at $0.10 EPS, FY2027 earnings at $0.30 EPS and FY2028 earnings at $0.55 EPS.

Other equities research analysts have also recently issued research reports about the company. StockNews.com cut Akebia Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, April 25th. Jefferies Financial Group initiated coverage on Akebia Therapeutics in a research note on Tuesday, April 1st. They set a “buy” rating and a $6.00 price target for the company. Piper Sandler upped their price target on Akebia Therapeutics from $4.00 to $6.00 and gave the stock an “overweight” rating in a research note on Friday, March 14th. Leerink Partners initiated coverage on Akebia Therapeutics in a research report on Monday. They issued an “outperform” rating and a $7.00 price objective for the company. Finally, HC Wainwright restated a “buy” rating and set a $7.50 target price on shares of Akebia Therapeutics in a research report on Friday, April 4th. One analyst has rated the stock with a sell rating, four have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $6.63.

Akebia Therapeutics Price Performance

Akebia Therapeutics stock opened at $2.39 on Thursday. Akebia Therapeutics has a 12 month low of $0.80 and a 12 month high of $2.89. The business has a 50 day simple moving average of $1.99 and a 200-day simple moving average of $1.94. The stock has a market capitalization of $564.59 million, a PE ratio of -10.39 and a beta of 0.87.

Akebia Therapeutics (NASDAQ:AKBA) last issued its quarterly earnings data on Thursday, March 13th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.05). The business had revenue of $46.50 million during the quarter, compared to the consensus estimate of $37.36 million.

Insider Buying and Selling

In other Akebia Therapeutics news, CEO John P. Butler sold 144,250 shares of the company’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $2.10, for a total value of $302,925.00. Following the sale, the chief executive officer now owns 2,604,330 shares of the company’s stock, valued at $5,469,093. This represents a 5.25 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Richard C. Malabre sold 30,202 shares of the company’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $2.10, for a total transaction of $63,424.20. Following the completion of the sale, the chief accounting officer now directly owns 280,248 shares in the company, valued at $588,520.80. This trade represents a 9.73 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 280,579 shares of company stock valued at $589,216. Corporate insiders own 4.10% of the company’s stock.

Hedge Funds Weigh In On Akebia Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. SRS Capital Advisors Inc. purchased a new position in shares of Akebia Therapeutics during the fourth quarter valued at approximately $26,000. Mariner LLC purchased a new position in shares of Akebia Therapeutics during the fourth quarter valued at approximately $28,000. PDS Planning Inc acquired a new position in Akebia Therapeutics during the fourth quarter worth approximately $28,000. Unified Investment Management raised its stake in Akebia Therapeutics by 47.8% during the first quarter. Unified Investment Management now owns 17,000 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 5,500 shares during the period. Finally, Cibc World Markets Corp purchased a new position in Akebia Therapeutics during the fourth quarter worth approximately $37,000. Hedge funds and other institutional investors own 33.92% of the company’s stock.

About Akebia Therapeutics

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.